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Background: Osteoarthritis (OA) is a multi-factorial disease leading progressively to loss of articular cartilage and
subsequently to loss of joint function. While hypertrophy of chondrocytes is a physiological process implicated in
the longitudinal growth of long bones, hypertrophy-like alterations in chondrocytes play a major role in OA. We
performed a quantitative proteomic analysis in osteoarthritic and normal chondrocytes followed by functional
analyses to investigate proteome changes and molecular pathways involved in OA pathogenesis.
Methods: Chondrocytes were isolated from articular cartilage of ten patients with primary OA undergoing knee
replacement surgery and six normal donors undergoing fracture repair surgery without history of joint disease and
no OA clinical manifestations. We analyzed the proteome of chondrocytes using high resolution mass spectrometry
and quantified it by label-free quantification and western blot analysis. We also used WebGestalt, a web-based
enrichment tool for the functional annotation and pathway analysis of the differentially synthesized proteins,
using the Wikipathways database. ClueGO, a Cytoscape plug-in, is also used to compare groups of proteins and
to visualize the functionally organized Gene Ontology (GO) terms and pathways in the form of dynamical network
structures.
Results: The proteomic analysis led to the identification of a total of ~2400 proteins. 269 of them showed
differential synthesis levels between the two groups. Using functional annotation, we found that proteins
belonging to pathways associated with regulation of the actin cytoskeleton, EGF/EGFR, TGF-β, MAPK signaling,
integrin-mediated cell adhesion, and lipid metabolism were significantly enriched in the OA samples (p ≤10−5).
We also observed that the proteins GSTP1, PLS3, MYOF, HSD17B12, PRDX2, APCS, PLA2G2A SERPINH1/HSP47 and
MVP, show distinct synthesis levels, characteristic for OA or control chondrocytes.
Conclusion: In this study we compared the quantitative changes in proteins synthesized in osteoarthritic compared
to normal chondrocytes. We identified several pathways and proteins to be associated with OA chondrocytes. This
study provides evidence for further testing on the molecular mechanism of the disease and also propose proteins
as candidate markers of OA chondrocyte phenotype.
Keywords: Osteoarthritis, Cartilage, Chondrocytes, Proteomics, Mass spectrometry, Pathway analysis, PLS3, GSTP1* Correspondence: tassos.economou@rega.kuleuven.be
1Institute of Molecular Biology and Biotechnology – FoRTH, Iraklio, Greece
2Department of Microbiology and Immunology, Rega Institute for Medical
Research, KULeuven, Leuven, Belgium
Full list of author information is available at the end of the article
© 2015 Tsolis et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Tsolis et al. Clinical Proteomics  (2015) 12:12 Page 2 of 16Background
Osteoarthritis (OA) is the most common form of arthritis
and a major cause of disability worldwide. OA affects the
whole joint, leading to cartilage degradation, synovial
inflammation and subchondral bone remodelling [1,2].
Disease progression is slow. Structural alterations start
before middle age but can be diagnosed when they
become symptomatic where at that time there is a severe
damage in the joint. The aetiology of the disease is not
completely defined [1-5]. Several patho-physiological
processes are involved in the disease phenotype, however
the triggering event for disease onset is unknown, as a
result OA is considered a multi-factorial disease [1,3,6-8].
Several risk factors have been associated with OA,
including age, obesity, mechanical load, genetic predis-
position, sex, and prior joint injury [7,9].
Currently, there is not efficient treatment for OA.
Recommended pharmacological interventions aim for
the relief of pain and joint inflammation by administration
of mild analgesics first and non-steroid anti-inflammatory
drugs (NSAIDs), later [10,11]. Intra-articular injection of
hyaluronic acid (HA) or corticosteroids was also shown to
improve pain, whereas the HA administration showed
more prolonged effect [10,11]. Another approach that is
currently under research for the management of OA,
is the use of disease-modifying osteoarthritis drugs
(DMOADs) (e.g. bisphosphonates, doxycycline, strontium
ranelate) [12,13]. This category of drugs slows down the
cartilage degradation, stalling or reducing the disease
progression. Other approaches aiming for the regeneration
of cartilage, make use of growth factors or cytokines,
either by direct injection to the infected areas or
using platelet-rich plasma or gene therapy approaches
[10,13-15]. All these methods were tested in animal
models and clinical trials, however further studies are
needed to verify their efficacy and the prerequisites in
which these approaches could be beneficial. Collectively,
the latest approaches for the management of OA highlight
the importance of unravelling the molecular mechanism
of OA progression, in order to design more targeted and
effective therapeutic strategies.
Chondrocytes comprise the cell population responsible
for cartilage homeostasis. During OA progression,
chondrocytes acquire a hypertrophic phenotype, showing
increased synthesis of several markers including COL10A1,
MMP-13 and Runx2 [16]. Even though there is a wealth of
information about chondrocyte differentiation mechanisms,
it is not completely understood how chondrocytes are
affected during the progression of osteoarthritis [16-18].
Different -omics approaches have been used for the
identification of the alterations that occur in articular
chondrocytes during OA progression. Previous proteomics
studies highlighted mitochondrial dysfunction and redox
imbalance in osteoarthritic chondrocytes [19,20]. Anotherstudy, combining genomics and lipidomics analysis
revealed that OA articular chondrocytes generate multiple
eicosanoid products which show a complex role in cartilage
homeostasis and pathophysiology of the disease [21].
The aim of this study was to improve our understanding
of the molecular basis of OA by performing a comparative
proteomic analysis of articular chondrocytes derived from
patients with OA and from disease-free individuals, using
high-resolution mass spectrometry and label-free quantifi-
cation. 269 proteins showed significantly differential syn-
thesis between patients and controls and these were
functionally annotated and linked through network ana-
lysis, for the identification of substantially enriched path-
ways, related with the disease. Pathway analysis showed
enrichment in those related to the cytoskeleton, adhesion
and lipid metabolism. Also, we propose that eight of the
identified proteins (GSTP1, PLS3, MYOF, HSD17B12,
PRDX2, APCS, PLA2G2A SERPINH1/HSP47 and MVP)
could be used as potential markers for chondrocyte
differentiation, since they show high difference in
abundance levels and are identified with a very high
frequency in the sample population that was tested.
Results
Identified and differentially synthesized proteins
About 2,400 proteins were identified in total in all
samples at least once (see Methods; Additional file 1 –
“Total Proteins Identified”). To ensure robustness of
identification of proteins as characteristic of one or the
other or both study groups we imposed stringent criteria
(see Methods). A total of 142 unique and 937 common
proteins were thus confidently assigned (Figure 1,
Additional file 1 – “Unique IDs in OA”, “Unique IDs
in controls”, “Common Proteome-filtered”). None of the
peptides of the unique proteins could be identified in the
opposite study group. Lack of identification for a given
protein indicates that it is either not synthesized at
all or that it exists in amounts that are below detection
[22] (see below).
The majority of the identified proteins (~85%) was
found in both study groups and presumably reflects the
common chondrocyte proteome. Attesting to this, many
of the proteins characteristic for chondrocytes, e.g. ACAN,
COL2A1 were identified [23]. To determine over- or
under-synthesized proteins in the “common” dataset, we
compared the quantitative values in the OA and control
groups. For this, a spectral counting label-free quantifica-
tion approach was used in the identified proteins, as
implemented in Scaffold software [24]. The abundance of
proteins of the “common proteome” was tested for statis-
tical significance by applying a t-test [25]. Also, in the
same subset the fold change was calculated by dividing
the mean quantitative value of the OA group with the
mean quantitative value of the control group. Significantly
Figure 1 Proteomic data analysis workflow. Experimentally identified proteins were filtered for the identification of differently synthesized
proteins (see Methods). Two protein sets (one for controls and one for OA) were then functionally annotated using WebGestalt and ClueGO.
In addition, 9 proteins robustly identified but poorly described in databases, were selected.
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have p-values <0.05 and fold change > 2 (or log2 fold
change > 1), whereas in the control group those that have
a p-value <0.05 and fold change < 0.5 (or log2 fold
change < −1) (Figure 1). Overall, 127 of the proteins
shared between the chondrocytes from the OA and
control groups, showed differential abundance (42 of
them shown in Figure 2; for the complete set see
Additional file 1 – “Over-synthesized in OA” and
“Under-synthesized in OA”).
Protein copy numbers in a eukaryotic cell show a
broad distribution, ranging across at least seven orders
of magnitude [26]. Previous proteomics studies have
shown similarities in protein levels between cell lines
and also certain differences [27,28]. To estimate the
lowest protein amounts that can be commonly detected
in our study, we compared the abundance of identified
proteins to that from a reference study carried out using
a human cell-line [26]. Most of the proteins identified
here, correspond to those of moderate to high abundance
in the reference dataset (Figure 3). However, several other
proteins that we identified using strict criteria and filtering
based on frequency of identification (see Methods), fell in
the low-abundance group of the reference set (Figure 3,
black bars). This suggests that our pipeline has a signifi-
cant identification depth (down to 5x102 molecules/cell).
In addition, we see that the filtering step that we include is
important for the removal of random identifications.-16
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Figure 2 Over-/under-synthezied proteins in OA chondrocytes. Several com
OA chondrocytes, compared to the control group. The complete table with
“Common Proteome – Filtered”.When we analyze our dataset using more loose criteria
(protein FDR = 1% and minimum number identified
peptides per protein = 1) we can identify ~7,000 proteins
in total. If in this dataset we apply filtering based on the
frequency of identified samples, we end up with ~1,400
proteins, reducing that way the number of missing values
in the dataset.
Bioinformatic analysis for enriched terms
We next sought to determine biological processes and
pathways that may be associated with OA pathogenesis
in our experimental dataset. For this, we used in silico
tools to determine which proteins or biological terms or
pathways are enriched in the identified proteins. First, we
used WebGestalt [29,30], which performs a hypergeo-
metric test for the enrichment of GO terms and pathways
in the selected proteins, followed by the Benjamini &
Hochberg (BH) method for multiple test adjustment (adjP).
We analyzed the 269 unique or differentially synthesized
proteins in our dataset (Figure 1; Additional file 1 –
“Unique IDs in OA”, “Over-synthesized in OA”,
“Under-synthesized in OA”, “Unique IDs in Controls”),
divided in two sets: the first consisted of 120 over-
synthesized and 131 unique proteins in OA patients; the
second consisted of seven under-synthesized proteins in
the patients’ group and 11 unique proteins in the control
subjects. Below we present a summary of the results of
the WebGestalt analysis.B
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Figure 3 Estimated abundance for the experimentally identified proteins. Experimentally identified proteins were compared with a reference
dataset of an osteosarcoma cell line (U2OS cell line) [26]. X-axis: copies per cell, for the proteins identified in the reference proteome; Y-axis:
number of proteins correspond to a specific abundance window. We align the experimentally identified proteins with the reference set, and plot
the number of proteins from this study that correspond to the reference abundance levels. Light grey histogram: protein abundance distribution
of the reference set; mild grey: protein abundance of 4,169 from the 7,367 of experimentally identified proteins using loose criteria (protein FDR = 1%
and minimum number of peptides = 1); dark grey: experimentally identified proteins (1% FDR, min 1 peptides) filtered based on the frequency of
identification of each protein in the biological samples, using criteria described in Methods (1,194 of 1,475 proteins are plotted); back columns: filtered
experimentally identified proteins as described in Figure 1 - venn diagram (947 of the 1,079 proteins are plotted).
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We identified enriched terms for the categories “biological
process” (BP), and “cellular compartment” (CC) of GO
between the differentially synthesized proteins of each
group (see “Statistical and Enrichment Analysis”, Methods).
Enriched GO terms (adjP ≤10−5) for each of the BP and CC
can be grouped into 10 generic functional categories.
Figure 4 illustrates the percentage of proteins that belong
to selected generic functional categories from the proteins
that are enriched or uniquely identified in each of the study
groups (OA or control) (Additional file 2 – Cluster 2
“Protein Set for normal chondrocytes”; Additional file 3 –
Cluster 1 “Protein Set for OA chondrocytes”). An
extended table with enriched GO terms is included in
Additional file 4. Proteins related to metabolic processes,
are equally assigned in both study groups, reflecting that
common mechanisms of the cell are retained during
disease (Figure 4). In OA chondrocytes a high percentage
of the differentially synthesized proteins are related to
biological processes such as localization and transport
mechanisms of the cell, categories that are less repre-
sented in control chondrocytes. For the GO category
“cellular compartment”, proteins related to the extracellu-
lar matrix are significantly under-synthesized in OA
chondrocytes (Figure 4). Proteins that form part of cellular
organelles are significantly over-synthesized in OAchondrocytes. The remaining groups for BP and CC
tested did not show any significant difference between
groups (data not shown). These changes clearly highlight
that hypertrophic osteoarthritic chondrocytes are pheno-
typically different from control cells and harbour character-
istic proteomic signatures.
Enrichment analysis of GO-terms using ClueGO
To further probe the GO enrichment analysis presented
above, we made use of the ClueGO plug-in of Cytoscape
3.1.0, which enables comparison of clusters/groups to high-
light their functional specificity. For this, two protein sets
were uploaded in ClueGO (Additional file 2 – Cluster 2
“Protein Set for normal chondrocytes”; Additional file 3 –
Cluster 1 “Protein Set for OA chondrocytes”) and were
compared to each other by applying appropriate settings
(see Methods).
ClueGO was used for the integration of GO terms as well
as the generation and visualization of a functionally
arranged GO term network that exposes the relations
between the GO terms based on the similarity of their asso-
ciated proteins. ClueGO utilizes kappa statistics, in a similar
way as described by Huang et al. [31], to connect the GO
terms in the network. Briefly, kappa statistics refers to the
quantitative measurement of the degree of agreement on
how proteins share similar annotation of GO terms.
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Figure 4 Differentially enriched GO Terms between OA and normal
chondrocytes. Differentially synthesized proteins (over-/under-synthesized
in OA and uniquely identified proteins) for each group were
tested for enrichment in GO terms of biological process and cellular
compartment. A high percentage of the proteins belonging to OA
group are associated with localization and transport biological
functions. The majority of the proteins related to the control group are
localized in the extracellular region whereas a higher percentage of
the proteins associated with the OA chondrocytes is a part of cellular
organelles. Percentages correspond to the number of proteins of each
group, associated with a specific term from the total proteins of the
specific group. An extended table with the enriched GO terms is
provided in Additional file 4.
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processes” were highly enriched (Figure 5, Groups A-C).
The first group contains terms related with regulation of
cytoskeleton. The second group is related to the translation
process and the third group is related to intracellular
transport. Collectively, these data indicate that three
groups of biological processes (cytoskeleton organization,
translation and intracellular transport) are altered in OA
chondrocytes.
Pathway enrichment analysis
To examine which biological pathways are apparently
altered in the OA chondrocytes, we next performed a
pathway analysis. Differentially synthesized proteins in
OA chondrocytes were searched against the Wikipathways
database, using WebGestalt [29,30]. Enriched pathways
were grouped into four categories, based on the biological
processes that they participate in (Table 1). The first group
contains pathways related with general metabolic pro-
cesses like proteasome, ribosome, electron transport etc.
Even if these pathways do not necessarily pinpoint the
precise molecular mechanism of the disease, suggest that
OA chondrocytes are metabolically more active, compared
to control chondrocytes.The second group includes pathways related with
remodeling of cytoskeleton and endocytosis. Pathways
mediating focal adhesion, integrin-mediated cell adhesion,
G13 and TOR signaling are used in several biological
processes including cell motility and proliferation, cell
differentiation and gene expression or cell survival and cell
cycle regulation, often linking extracellular signals with
other intracellular signaling pathways. Several intracellular
signaling pathways were also identified in pathway analysis
and are listed in the third group. Proteins belonging
to EGF-EGFR, TGF-beta, TNF-alpha, MAPK, Wnt,
CRH, androgen receptor, senescence and autophagy
and TSH signaling pathways showed altered synthesis
in hypertrophic chondrocytes. Signaling through these
pathways has been described in the literature during
normal chondrocyte differentiation or development of
the OA disease [32-39]. Two more signaling pathways,
TWEAK and RANKL-RANK signaling pathways, which
are associated with the production of pro-inflammatory
cytokines and bone development were also enriched in
OA chondrocytes [40,41].
The fourth group of enriched pathways includes those
related to lipid metabolism and oxidative stress. Proteins
participating in fatty acid beta oxidation and enzymes of
the cytochrome p450, apart from their role in the metab-
olism of lipids and chemical compounds, are also used for
the metabolism of eicosanoids and other secondary
metabolites [42].
Proteins with synthesis characteristic to each group
We next searched for proteins that show distinct synthesis
in each group, and potentially underscore the phenotypic
shift in OA chondrocytes. Most in silico function
annotation tools use public pathway databases to assign
the identified proteins/genes to specific pathways.
However, several proteins are not included in these
databases, mainly because their interactions are not
completely defined, and cannot be functionally annotated
by the pathway enrichment tools. In our dataset, there
were a few such proteins, which show distinct synthesis
patterns between OA and normal chondrocytes, and are
not included in the in silico pathway analysis described
above, or their protein function is not completely described
by the pathway analysis.
We selected proteins that are not previously described
in OA chondrocytes and are among the most confidently
identified proteins (show very high frequency of identifica-
tion between all samples and have high number of spectra
in the label-free quantification). We ended up with nine
proteins (HSD17B12, PLA2G2A, APCS, PRDX2, GSTP1,
PLS3, SERPINH1, MVP, MYOF), described in Figure 6A.
Eight of them are differentially synthesized between OA
and normal chondrocytes whereas HSD17B12 is iden-
tified only in OA chondrocytes with very high frequency
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Figure 5 Enriched GO network groups using ClueGO. Biological processes (GO category) of the identified over- and under-synthesized proteins
in our experimental dataset were visualized with ClueGO (kappa score≥ 0.3) as a functional grouped network and only the most significant
interactions are shown. Each node represents a biological process. Edges represent connections between the nodes and the length of each edge
reflects the relatedness of two processes. The specific functional terms that were used to generate the network in Cytoscape resulted from the
comparison of the two clusters (OA and controls; see Methods). The most significant parent or child term per group is shown in the ClueGO grouped
network as a group title (A. Cellular component disassembly; B. Translation; C. Intracellular transport). The enrichment significance of the GO terms is
reflected by the size of the nodes. Node color, represents the class that they belong. Mixed coloring means that the specific node belongs to multiple
classes. Ungrouped terms are not shown.
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the validation of the quantification method (ACAN,
COL2A1, TG2, CTSB, CTNNB1) (Figure 6A). All of the
control proteins showed similar synthesis pattern as
expected [35,43-45].
To corroborate the label-free quantification approach, we
performed western blot analysis for two of the selectedproteins (GSTP1 and PLS3), in four new samples of OA
chondrocytes and equal number of controls (Figure 6B-E).
For loading control and normalization between samples we
probed for β-actin. Western blot analysis was in agreement
with the mass spectrometric label-free quantification. The
two proteins were found in 2.5 and 2 fold higher abundance
in OA patients than in the controls, accordingly.
Table 1 Enriched pathways in OA chondrocytes
PathwayName Gene Names AdjP-value
General metabolism and cellular processes
Parkin-Ubiquitin Proteasomal System pathway TUBA1C PSMD4 HSPA1A PSMD2 PSMD6 HSPA2 PSMC1 TUBB adjP = 1.47e-07
Translation Factors EIF3E EIF4A1 EEF1G EEF1A1 EEF2 EIF3B EEF1D adjP = 2.60e-07
Electron Transport Chain ATP5B COX6C SLC25A5 UQCRFS1 NDUFB4 ATP5A1 adjP = 0.0001
Cytoplasmic Ribosomal Proteins RPL8 RPLP0 RPL35A RPL23 RPL10 RPL27 adjP = 8.18e-05
Proteasome Degradation PSMD4 PSMD2 PSMD6 PSMC1 adjP = 0.0018
TCA Cycle SUCLA2 IDH3G DLST adjP = 0.0007
Oxidative phosphorylation ATP5B NDUFB4 ATP5A1 adjP = 0.0098
Adhesion, cytoskeleton remodeling, cell-cell & cell-matrix interactions, endocytosis
Focal Adhesion ACTG1 RAC1 RAP1B FLNA VASP MAPK1 PDGFRB CAPN1 adjP = 8.18e-05
Regulation of Actin Cytoskeleton ACTG1 IQGAP1 RAC1 ENAH GSN PFN1 MAPK1 PDGFRB adjP = 3.12e-05
Integrin-mediated cell adhesion RAC1 RAP1B CAPN2 VASP MAPK1 CAPN1 adjP = 0.0001
Synaptic Vesicle Pathway AP2A2 AP2A1 CLTC AP2B1 NAPA adjP = 8.74e-05
G13 Signaling Pathway IQGAP1 RAC1 PFN1 adjP = 0.0034
TOR signaling RAC1 RRAGC PRKAG1 adjP = 0.0032
Senescence and Autophagy GSN MMP14 CD44 MAPK1 adjP = 0.0100
Signaling pathways
EGF-EGFR Signaling Pathway GJA1 IQGAP1 RAC1 HGS AP2A1 AP2B1 MAPK1 adjP = 0.0003
TGF beta Signaling Pathway RAC1 HGS TRAP1 SPTBN1 SKP1 MAPK1 PRKAR2A adjP = 0.0001
TNF alpha Signaling Pathway RAC1 PSMD2 TRAP1 BAX SKP1 HSP90AA1 MAPK1 adjP = 2.36e-05
MAPK signaling pathway RAC1 RAP1B FLNA MAPK1 PDGFRB adjP = 0.0058
Wnt Signaling Pathway GJA1 RAC1 CTNNB1 adjP = 0.0063
Corticotropin-releasing hormone GJA1 RAP1B GNB2 GNAS CTNNB1 HSP90AA1 MAPK1 GNAI2 adjP = 6.10e-06
Androgen receptor signaling pathway RAC1 FHL2 FLNA CTNNB1 CARM1 adjP = 0.0007
TSH signaling pathway RAP1B GNAS MAPK1 GNAI2 adjP = 0.0021
TWEAK Signaling Pathway RAC1 CTNNB1 MAPK1 adjP = 0.0083
RANKL-RANK Signaling Pathway RAC1 FHL2 MAPK1 adjP = 0.0121
Lipid metabolism, eicosanoid metabolism, oxidative stress
metapathway biotransformation CYP20A1 GSTT1 GSTP1 GSTK1 GPX4 CYP1B1 EPHX1 adjP = 0.0003
cytochrome P450 CYP20A1 CYB5R1 CYP1B1 CYB5R3 adjP = 0.0018
Fatty Acid Beta Oxidation CHKB SLC25A20 DECR1 adjP = 0.0148
Prostaglandin Synthesis and Regulation ANXA6 ANXA1 ANXA2 adjP = 0.0023
Glutathione metabolism GSTT1 GPX4 adjP = 0.0150
Differently synthesized proteins in OA chondrocytes were subjected to pathway analysis, by querying the Wikipathways database, using the WebGestalt web tool.
Enriched pathways are grouped into four categories based on the biological processes participating. Proteins assigned to each pathway are listed in “gene names”
column. AdjP-value corresponds to p-value adjusted by the multiple test adjustment, during enrichment test.
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To probe the multifactorial nature of osteoarthritis, we
used an –omics approach that offers a broad, unbiased
view of the OA landscape, in order to improve our
understanding on the molecular base of the disease.
We performed a quantitative comparative proteomic
analysis, of osteoarthritic and normal chondrocytes,
combined with bioinformatics analysis.
During OA progression, chondrocytes acquire a hyper-
trophic phenotype, characterized by altered synthesis ofmany proteins related to normal development and cartilage
turnover. Hypertrophy is a physiological stage in chondro-
cyte differentiation, and an essential step during bone
development [17,18,46,47]. In this study, we showed that
hypertrophic osteoarthritic chondrocytes possess a distinct
synthesized proteome compared to that of the control
group. Major biological processes that are affected during
disease progression, are related to the cytoskeleton,
cell-cell and cell-ECM interactions. In agreement with
this, several proteins over-synthesized in OA chondrocytes
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Figure 6 Differentially synthesized proteins. A) Proteins with different abundance levels between the two groups, as determined by label-free
quantification after LC-MS. Quantitative values shown correspond to average values between the total samples in which a given protein was
identified (ACAN: OA = 9, control = 6; COL2A1: OA = 5, control = 5; TG2: OA = 10, control = 6; CTSB: OA = 10, control = 6; CTNNB1: OA = 9,
control = 0; HSD17B12: OA = 9, control = 0; PLA2G2A: OA = 5, control = 5; APCS: OA = 4, control = 5; PRDX2: OA = 10, control = 6; GSTP1: OA = 10,
control = 6; PLS3: OA = 10, control = 5; SERPINH1/HSP47: OA = 9, control 6; MVP: OA = 10, control = 6; MYOF: OA = 10, control = 6). Error-bars
correspond to ±1 s.e. B) Western blot analysis for the validation of label-free quantication method, using antibodies against GSTP1 and PLS3 in
four different OA and control samples. Values are normalized to β-actin. Error-bars correspond to ±1 s.e. C) Quantitation (arbitrary units) of GSTP1
per sample. D) Quantitation (arbitrary units) of PLS3 per sample E) Quantitation (arbitrary units) of β-actin per sample.
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Network analysis for GO terms, using ClueGO (Figure 5),
showed that a significant number of the differentially
synthesized proteins cluster together having biological
functions related to the cytoskeleton, whereas several
pathways, such as regulation of actin cytoskeleton,
integrin-mediated adhesion and the G13 and TOR
signaling pathways where found enriched in OA chon-
drocytes (Table 1). The interaction of chondrocytes with
ECM molecules has been shown to affect cytoskeletal
organization, proliferation, differentiation, and gene expres-
sion in chondrocytes [48-54]. Also, it is noted that the
micro-environment of cartilage possibly triggers an autoph-
agy response in the hypoxic chondrocytes [55]. Collectively,
these data demonstrate a global view of cytoskeleton-
related changes associated with OA chondrocytes.Several signaling pathways are activated during chon-
drocyte differentiation [16,46]. Apart from cytoskeleton-
related pathways, we also found that other signaling path-
ways are enriched in OA chondrocytes. These include
EGF-EGFR, TGF-beta, TNF-alpha, MAPK and Wnt
canonical and non-canonical signaling pathways, TWEAK
and RANKL-RANK signaling pathways (Table 1). Signaling
through those pathways has been reported to occur during
normal chondrocyte differentiation or OA development in
arthritis models, whereas the RANKL-RANK pathway
was also proposed as a target for treatment of OA
[16,32-35,40,41,46,56-58].
In addition, pathway enrichment analysis showed that
signaling through corticotrophin releasing hormone
(CRH), androgen receptor (AR) and thryroid stimulating
hormone (TSH) is also affected in OA chondrocytes.
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its enrichment could possibly reflect joint inflammation
[37]. Expression of AR in articular chondrocytes was
assessed in human and mouse biopsies. The percentage of
cells showing increased expression of AR is increased in
resting and hypertrophic zones compared to the pro-
liferative zone, suggesting that signaling through AR
might be used during normal chondrocyte differentiation
[36,59]. Also, differentiation of mesenchymal stem cells
into chondrocyte-like cells was observed after treatment
with TSH [60]. However, the authors conclude that
further studies are needed in order to determine the
exact role of TSH in the chondrocyte differentiation
process and whether this pathway may promote osteogenic
differentiation, as well.
Another group of pathways that is enriched in OA
chondrocytes includes those related to lipid metabolism,
prostaglandin synthesis, glutathione metabolism and
metabolism through the cytochrome p450 (Table 1).
Enzymes of those pathways are also used for the
metabolism of eicosanoids [42]. Several secondary metabo-
lites, including prostaglandins (PG), epoxyeicosanoic acids
(EET), hydroxyeicosatetranoic acids (HETE) are synthe-
sized from eicosanoids, and regulate a plethora of bio-
logical functions, including inflammation, cell growth,
survival, migration and invasion [42,61-66]. Altered
eicosanoid metabolism was reported before in OA articu-
lar chondrocytes [21]. Elevated synthesis of proteins of
glutathione metabolism could be induced by increased
oxidative stress in the OA cells, a finding that is corrobo-
rated by another proteomic study [20]. In addition, we
found several proteins, which are related with previously
described biological processes, but which have not yet
been related to OA or shown to be over-synthesized in
OA chondrocytes. These include mainly GSTP1 and
HSD17B12 (Figure 6A). The levels of GSTP1 protein were
also verified using WB (Figure 6B). GSTP1 is important
for metabolite detoxification [67]. Over-expression of the
GSTP1 gene was observed in several cancer types and is
considered to be a marker for cancer development [68].
Additionally, GSTP interacts directly and can inhibit c-Jun
N-terminal kinase (JNK), affecting that way processes like
apoptosis, differentiation and proliferation [68-70]. The
expression of HSD17B12 was associated with the meta-
static phenotype in tumor cell lines, through its function
in Arachinoid Acid (AA) metabolism, linking the metabol-
ism of eicosanoids and cytoskeleton remodeling [71,72].
Thus, activation of lipid metabolism pathways, might lead
to altered production of secondary metabolites which in
turn support cytoskeleton reorganization during synovial
inflammation and chondrocyte differentiation, phenotypes
well defined during OA.
Two more proteins which are over-synthesized in
OA chondrocytes, and are associated with the observedphenotype are PLS3 and MYOF. PLS3 synthesis levels
were also verified with WB (Figure 6B). Pathogenic vari-
ants of this protein were found in families with X-linked
osteoporosis and fractures, suggesting that PLS3 might be
important in human bone health [73]. The synthesis levels
and function of PLS3 has not been studied in chondro-
cytes. Over-synthesis of PLS3 was found in cancer cells
and is proposed as a marker of circulating tumor cells
(CTCs) [74]. The exact function of PLS3 is not defined.
However, it seems to function as a key downstream mol-
ecule in the TGF-β pathway [75]. In addition, we observed
significantly increased synthesis of MYOF in OA chondro-
cytes, a protein that is related to membrane repair by an
unknown mechanism [76,77]. Over-synthesis of MYOF in
breast cancer cell lines leads to an increased invasion
phenotype and secretion of matrix metalloproteinases
(MMPs), while silencing of the gene restores the normal
phenotype, possibly by blocking the EGFR signaling
pathway [78,79]. Both proteins seem to have a key func-
tional role, since silencing of their genes can reverse the
phenotype induced by the initial stimuli.
Additionally, we identified five more proteins with
distinct synthesis between OA and control chondro-
cytes, and for which we do not have any knowledge
about the function in relation to the disease. From
these proteins PRDX2, SERPINH1/HSP47 and MVP
are over-synthesized in OA chondrocytes, whereas APCS
and PLA2G2A are mainly synthesized in control chondro-
cytes (Figure 6A). Peroxiredoxin-2 (PRDX2) is a member of
a class of thiol peroxidases and is hypothesized to act as a
redox sensor [80]. SERPINH1/HSP47 is a collagen specific
molecular chaperone, essential for the maturation of type I
and type III collagens [81]. Major vault protein (MVP) is an
evolutionally conserved, high abundant protein that seems
to play a role in drug resistance and in signaling pathways,
however its role is not understood [82,83]. Serum amyloid
P component (APCS) is a member of pentraxin family of
proteins, that plays a role in innate immune responses [84].
Its presence in cartilage was previously reported, however
nothing is known about the role of this protein in OA [85].
Finally, the membrane-associated form of phospholipase
A2 (PLA2G2A), is also highly synthesized in control
chondrocytes compared to the OA, but the function
of this protein is unknown [86].
Conclusion
In summary, we observed that OA chondrocytes display
molecular signatures of the hypertrophic phenotype,
where several pathways including adhesion, proliferation,
growth, and lipid metabolism are enriched. We propose
that the expression of the proteins GSTP1, PLS3, MYOF,
HSD17B12, PRDX2, APCS, PLA2G2A SERPINH1/HSP47
and MVP also reflect the altered phenotype of OA chondro-
cytes. Our study provides a number of testable hypotheses
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process pathways in osteoarthritis.
Methods
Cartilage tissue samples
Articular cartilage samples were obtained from femoral
heads, femoral condyles and tibial plateaus of patients
with primary osteoarthritis undergoing knee replace-
ment surgery at the Orthopaedics Department of the
University Hospital of Larissa [87]. Ten OA patients
who had undergone total knee replacement surgery were
included. Each articular cartilage sample was categorized
according to its gross morphology as severely damaged
and was taken from the main defective area of maximal
load. Kellgren-Lawrence grading scale (K-L) was used
for the assessment of OA severity in OA and control
samples (Table 2) [88]. Patients with rheumatoid arthritis
and other autoimmune disease as well as chondrodyspla-
sias, infection-induced OA and post-traumatic OA were
excluded from the study. Normal cartilage was obtained
from six individuals undergoing fracture repair surgery,
with no history of joint disease. Both patients and healthy
individuals’ cartilage samples were obtained upon verbal
informed consent form all individuals. The method of
obtaining verbal consent was approved by the Institutional
Review Board of the University Hospital of Larissa. The
study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki as reflected in a priori
approval by the Local Ethical Committee of the University
Hospital of Larissa.Table 2 Samples information
Sample Group Sex K-L score
332OA OA F 4
393OA OA F 4
520 ΟΑ OA M 4
524OA OA F 3
525OA OA F 4
526OA OA F 4
529OA OA F 4
530OA OA F 4
532OA OA F 4
533OA OA F 4
150Α Controls F 1
151Α Controls M 0
152Α Controls M 0
153Α Controls F 0
154Α Controls M 1
175Α Controls F 0
10 OA and 6 control chondrocyte samples were studied. OA stage was
measured in Kellgren & Lawrence system (K-L).Primary cultures of human articular chondrocytes, normal
and osteoarthritic
Articular cartilage was transported from the surgical room
to the laboratory in HBSS medium (Hanks Balanced Salt
Solution). It was then immediately dissected and subjected
to sequential digestion with pronase (1 mg/ml; 90 min;
Roche Applied Science, Germany) and collagenase P
(1 mg/ml; 3 h; Roche Applied Science, Germany) at 37°C.
Chondrocytes were cultured in Dulbecco’s Modified
Eagles Medium/ Ham’s F-12 (DMEM/F-12) (GIBCO BRL,
UK) plus 5% fetal bovine serum (FBS) and 100 U/ml
penicillin-streptomycin and were incubated at 37°C under
a humidified 5% CO2 atmosphere. Chondrocytes were
kept in culture for maximum of two passages. Trypsin
was used for the detachment of chondrocytes during the
primary culture, while type II collagen and type I
collagen ratio was screened in all samples to exclude
dedifferentiation events.
Protein extraction from chondrocytes
OA and normal chondrocytes were trypsinized, collected
and centrifuged for 10 min at 543xg. The cell pellet was
washed with PBS and then centrifuged again for 10 min
at 543xg at 4°C. The cell pellet was resuspended in RIPA
lysis buffer (50 mM Tris/HCl pH 7.2, 150 mM NaCl, 1%
Triton X-100, 1% sodium deoxycholate, 0.1% SDS) and
incubated on ice for 30 min. Remaining cells where lysed
after sonication (3 rounds at 30% amplitute), using a tip
sonicator (VCX130, Sonics & Materials, Newtown,
USA). Samples were clarified via centrifugation (15 min;
13,000xg; 4°C), in a bench top centrifuge, and total pro-
tein content was calculated using the BCA method [89].
1D-SDS-PAGE and in-gel digestion
Proteins from each sample (50 μg) were precipitated
using trichloroacetic acid/acetone (final concentration of
25% TCA w/v; 4°C; 30 min). Proteins were precipitated
after centrifugation (15,000 g; 30 min; 4°C), in a bench-top
centrifuge. Protein pellets were washed twice with
ice-cold acetone, and precipitated via centrifugation,
as previously. Excess acetone was aspirated and the
protein pellet was air-dried. Precipitated proteins were
re-solubilized in a solution containing 1.5 M Tris/HCl
pH 8.8 and 6x sample buffer in a ratio of 2:1 and analyzed
by 1D-SDS-PAGE 4-10% (29:1 acrylamide/bisacrylamide).
Gels were stained with colloidal coomassie blue (Coomassie
G250, 10% phosphoric acid, 10% ammonium sulfate, 20%
methanol). Each lane was cut in 10 slices, and de-stained
after three washes with 50% acetonitrile/water and 50 mM
ammonium bicarbonate. Samples were reduced in the pres-
ence of 10 mM DTT (45 min; 56°C) and then washed and
alkylated in the presence of 55 mM IAA (45 min; 22oC,
shaking, in the dark). Gel slices were washed with 50 mM
ABS and proteins were digested with 0.1 μg trypsin
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Generated peptides were collected, after repeated washes
with nanopure-H2O, 50% ACN in low binding tubes
(Axygen, Union City, CA) and trypsin was quenched by
acidifying the sample with 1–2 μL trifluoroacetic acid
(TFA), until pH < 2. Peptides were dried under vacuum,
during centrifugation (Speedvac; Savant) and desalted
using STAGE tips [90]. The desalted peptides were then
lyophilized (Speedvac) and stored at −20°C until use.
LC-MS/MS analysis
Peptide samples were analyzed using nano-Reverse
Phase (RP) LC coupled to an LTQ-Orbitrap XL or an
Orbitrap QE instrument. In the first case, peptides were
separated by an EASY-nLC 1000 HPLC (Proxeon,
Thermo Fisher Scientific, Odense, Denmark) system on
a pre-packed column (Thermo, OD 360 μm, ID 50 μm,
15 cm, C18, 2 μm). A linear gradient was used 5-30%
from buffer A (99.9% water, 0.1% FA) to buffer B (9.9%
water, 0.1% FA, 90% ACN) run for 165 min (flow rate:
300 nL/min), and peptides were analyzed in an LTQ-
Orbitrap XL, at a resolution of 60,000 (FWHM) at m/z
400. CID fragmentation was performed on the 10 most
intense precursor ions using 60 seconds exclusion time.
For the analysis in the Orbitrap QE mass spectrometer,
peptides were separated in a Dionex UltiMate 3000
UHPLC system. The samples were separated using an
EasySpray C18 column (Thermo Scientific) in a linear
gradient using as buffer A (water 99.9%, FA 0.1%) and
buffer B (ACN 80%, water 20%, FA 0.1%). Gradient from
buffer A to buffer B was separated in five steps, 4% to
10% B (12 min) followed by 10-35% B (20 minutes),
35- 65% B (5 min) and a final elution and re-equilibration
step at 95% and 5% B respectively. The flow-rate was set
at 300 nL/min. The Q Exactive was operated in positive
ion mode (nanospray voltage 1.5 kV, source temperature
250°C). The instrument was operated in data-dependent
acquisition (DDA) mode with a survey MS scan at a reso-
lution of 70,000 for the mass range of m/z 400–1600 for
precursor ions, followed by MS/MS scans of the top 10
most intense peaks with +2, +3 and +4 charged ions above
a threshold ion count of 16,000 at 35,000 resolution using
normalized collision energy (NCE) of 25 eV with an isola-
tion window of 3.0 m/z, an apex trigger 5–15 sec and a
dynamic exclusion of 10 s. All data were acquired with
Xcalibur 2.2 software (Thermo Scientific).
MS data analysis
Raw files were processed in Proteome Discoverer v1.4
using the algorithms SEQUEST v1.1.0.263 and Mascot
v2.3.2. Spectra were searched against the Uniprot Human
reference database, without isoforms (Oct 2012, 20,505
entries) [91]. Precursor mass error was set to 10 ppm for
both Orbitrap mass spectrometers, and fragment masserror to 800 mmu or 20 mmu, for the LTQ Orbitrap XL
and Orbitrap QE, respectively. Enzyme cleavage was set to
trypsin, and maximally two missed cleavages were
allowed. Variable modifications selected were methionine
oxidation and N-terminal acetylation; constant modifica-
tion selected was S-Carbamidomethylation of cysteine res-
idues. All files were merged in Scaffold v3.4.5 (Proteome
Software, Portland, OR) for the comparative analysis.
Scores from both Mascot and SEQUEST algorithms was
used through the PeptideProphet and ProteinProphet
algorithms for the identification of proteins [92-94].
Thresholds for protein and peptide identification through
ProteinProphet and PeptideProphet algorithms were set
to 99% and 95% accordingly, for proteins with minimum 2
different peptides identified, resulting in a protein false
discovery rate (FDR) of <0.1%. For the label-free quantifi-
cation of the identified proteins, we used spectral counting
quantification through Scaffold software, which sums all
the spectra associated with a specific protein within the
sample and also includes these spectra that are shared
with other proteins [95].
Statistical and enrichment analyses
Protein lists were exported from Scaffold to Microsoft
Excel for further processing. To ensure robustness of
identification, we filtered-out proteins identified with a
low frequency. Specifically, we accepted as “uniquely
identified” proteins those, which were identified in at
least half of the samples of each group (n ≥ 3 in the
control group and n ≥ 5 in OA group). From the commonly
identified proteins between OA and control conditions, we
discarded proteins with a frequency of identification < 4
and <3, accordingly.
For the identification of differentially synthesized
proteins, we tested for statistical (t-test) and biological
(fold-change) significance. A two tail t-test was performed
in the filtered “common sub-proteome” described before
(n ≥ 3 in the control group and n ≥ 4 in OA group) [25].
Missing values were excluded. Also for the same sub-
proteome, the fold change of protein levels was calculated
by dividing the mean spectral counting quantitative value
in OA samples with the mean value of the control samples
for each of the proteins. Proteins that were significantly
“over-synthesized” or “under-synthesized” were these with
p-value ≤0.05 and a fold change ≥ 2.
For the enrichment analysis we divided these proteins
in two groups. The first group contains proteins that are
over-synthesized and uniquely identified in OA chondro-
cytes and the second group contains proteins which are
under-synthesized in OA chondrocytes, compared to
control samples, or were uniquely identified in control
chondrocytes. The two protein groups were submitted
separately to WebGestalt as lists of their respective
Entrez gene IDs in order to enable a distinct enrichment
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human genome, which is generated from prior knowledge
sorted into functionally related gene/protein groups.
WebGestalt performs the hypergeometric test for the
enrichment of GO terms and pathways in the selected
proteins, followed by the Benjamini & Hochberg (BH)
method for multiple test adjustment (adjP) [29,30]. As
we are testing multiple gene sets at the same time,
the p-values need to be adjusted. BH is implemented
to control for false positive (i.e. Type I) errors. Traditional
multiple-testing corrections, adjust p-values derived from
multiple statistical tests to correct for the occurrence of
false positives. BH ranks p-values in an ascending order,
multiplies them by the number of features, and divides
them by their corresponding rank [96]. Using WebGestalt,
we conducted a functional enrichment analysis for
Gene Ontology (GO) terms, as well as a pathway en-
richment analysis using the Wikipathways database
(http://www.wikipathways.org).
Cluster/Group comparison by ClueGO
ClueGO, a Cytoscape plug-in was used to visualize the
non-redundant GO terms and pathways in functionally
organized networks, which reflect the relations between
the biological terms based on the similarity of their linked
gene/proteins [97]. For the cluster/group comparison by
ClueGO, we used the two protein groups, as mentioned
above, in order to illustrate their functional differences.
Using the Cytoscape environment [98], the two protein
groups were uploaded in ClueGO as two separate clusters
(Additional file 2 – Cluster 2 “Protein Set for normal chon-
drocytes”; Additional file 3 – Cluster 1 “Protein Set for OA
chondrocytes”) from the text files, and were compared with
each other by applying the following settings.
For the enrichment of biological terms and groups, we
used the two-sided (Enrichment/Depletion) tests based
on the hyper-geometric distribution. We set the statistical
significance to 0.05 (p ≤ 0.05), and we used the Bonferroni
adjustment to correct the p-value for the terms and the
groups created by ClueGO. We used fusion criteria to
diminish the redundancy of the terms shared by similar
associated proteins, which allows one to maintain the most
representative parent or child term. The Kappa-statistics
score threshold was set to 0.3. Other analysis parameters
include: GO level intervals: (3–15); number of associated
proteins for cluster 1: (nine); number of associated proteins
for cluster 2: (one); OR 50% specific; GO Term Fusion;
Leading Group: Highest Significance; Group Merge: (50%).
Western blot analysis
Chondrocytes were lysed as previously described and
protein concentration was quantified using the Bradford
protein assay (Bio-Rad Protein Assay, BioRad, Hercules,
CA) with bovine serum albumin as standard. Cell lysatesfrom chondrocytes were electrophoresed and separated
on a 10% acrylamide gels and transferred to PVDF
membranes (Millipore) that were probed with poly-
clonal rabbit anti-GSTP1 and anti-PLS3 antibodies
(Sigma-Aldrich, Missouri, USA). Polyclonal rabbit Anti-
β-actin antibody was used as loading control (Sigma-
Aldrich, Missouri, USA). Signals were detected using
suitable immunoglobulin IgG conjugated with horseradish
peroxidase. Nitrocellulose membranes were exposed to
photographic film, which was scanned and intensities of
protein bands were determined using ImageJ software.
Other software
Images and vectors were processed using Adobe Illustrator
CS5 and Graphs were designed in GraphPad Prism.
Additional files
Additional file 1: Identified Proteins in OA and control
chondrocytes. Description of data: Total proteins identified in this study
and protein sub-groups based on the quantitative value and frequency
of identification (see Methods).
Additional file 2: Cluster 2 - Protein Set for normal chondrocytes.
Under-synthesized proteins in OA chondrocytes and Uniquely
identified proteins in normal chondrocytes.
Additional file 3: Cluster 1 - Protein Set for OA chondrocytes.
Over-synthesized in OA chondrocytes and Uniquely identified
proteins in OA chondrocytes.
Additional file 4: Enriched GO terms in differentially synthesized
proteins. Summary of detailed GO terms enriched in OA and control
chondrocytes, after GO enrichment analysis using WebGestalt.
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